Monte Rosa Therapeutics Inc GLUE
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if GLUE is a good fit for your portfolio.
News
-
Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
-
Monte Rosa Therapeutics Announces Initiation of IND Enabling Studies for MRT-8102, A First-in-Class NEK7 Directed Molecular Glue Degrader and NLRP3/IL-1β Pathway Inhibitor
-
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
Trading Information
- Previous Close Price
- $5.45
- Day Range
- $5.29–5.50
- 52-Week Range
- $2.44–8.84
- Bid/Ask
- $2.19 / $5.80
- Market Cap
- $267.32 Mil
- Volume/Avg
- 87,737 / 138,259
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, they employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their most advanced product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 133
- Website
- https://www.monterosatx.com
Comparables
Valuation
|
Metric
|
GLUE
|
VOR
|
CELC
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 1.49 | 0.76 | 2.91 |
Price/Sales | — | — | — |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
GLUE
|
VOR
|
CELC
|
|---|---|---|---|
Quick Ratio | 5.00 | 8.81 | 12.78 |
Current Ratio | 5.07 | 9.04 | 13.43 |
Interest Coverage | — | — | −12.43 |
Quick Ratio
GLUE
VOR
CELC
Profitability
|
Metric
|
GLUE
|
VOR
|
CELC
|
|---|---|---|---|
Return on Assets (Normalized) | −41.09% | −41.83% | −35.57% |
Return on Equity (Normalized) | −55.88% | −51.69% | −49.08% |
Return on Invested Capital (Normalized) | −48.85% | −47.03% | −39.21% |
Return on Assets
GLUE
VOR
CELC
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Gwrjyjbk | Bsm | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Zmsrtgmj | Cmxhkr | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Cjyrqfv | Cfknvn | $97.8 Bil | |
MRNA
| Moderna Inc | Cpxpqygw | Bdmkr | $41.3 Bil | |
ARGX
| argenx SE ADR | Jsnffjc | Nlmw | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Kkqrypgm | Ssh | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Vmwztwf | Pwdzpk | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Gdmrdbjyq | Lsqqcxq | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Yssvqcqmr | Zrltn | $12.5 Bil | |
INCY
| Incyte Corp | Jfzkndkk | Pbzssx | $11.6 Bil |